LIT-927 is a Locally and Orally Active CXCL12 Neutraligand with Anti-inflammatory Effect in a Murine Model of Allergic Airway Hypereosinophilia. displays a higher solubility. LIT-927 reduces eosinophil recruitment in a murine model of allergic airway hypereosinophilia. Combined with a high binding selectivity for CXCL12 over other chemokines, LIT-927 represents a powerful pharmacological tool to investigate CXCL12 physiology in vivo, and to explore the activity of chemokine neutralization in inflammatory and related diseases.
CXCR Inhibitors Related Products:
Plerixafor (AMD3100); Plerixafor 8HCl; WZ811; Navarixin; AMD 3465 hexahydrobromide